ArQule, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of pharmaceutical products. Its proprietary pipeline is directed towards molecular targets and biological processes with demonstrated roles in the development of human cancers. Its portfolio includes Tivantinib, ARQ 087, ARQ 092, ARQ 761, and ARQ 751. The company was founded in 1993 and is headquartered in Burlington, MA.
